Neurofeedback Study ADHD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- ADHD
- Sponsor
- Philipps University Marburg Medical Center
- Enrollment
- 120
- Locations
- 1
- Primary Endpoint
- Core ADHD symptoms (inattention/hyperactivity/impulsivity) objectively assessed with the computer based Qb-Test (go-no-go-task with infrared camera)
- Last Updated
- 9 years ago
Overview
Brief Summary
Neurofeedback has proved to be effective in treating Attention deficit hyperactivity disorder (ADHD) in experimental settings. This study investigates whether neurofeedback can be used as a therapeutic intervention in regular outpatient care. The investigators compare high frequent neurofeedback with high frequent self-management therapy and suppose that both result in comparable effects.
Investigators
Winfried Rief
Prof. Dr.
Philipps University Marburg Medical Center
Eligibility Criteria
Inclusion Criteria
- •children with ADHD aged 7 to 11
- •full command of the German language.
Exclusion Criteria
- •IQ below 80
- •Children with symptoms of:
- •inattention,
- •hyperactivity or
- •impulsivity due to other medical reasons such as:
- •hyperthyreosis,
- •epilepsy,
- •brain disorders and
- •any genetic or medical disorder associated with externalizing behavior that mimics ADHD.
Outcomes
Primary Outcomes
Core ADHD symptoms (inattention/hyperactivity/impulsivity) objectively assessed with the computer based Qb-Test (go-no-go-task with infrared camera)
Time Frame: Pre-Post-Change-Design; change for core symptoms from baseline to after 12 weeks, 6 and 12 months
Children perform the Qb-Test: * T1 baseline diagnostic before therapy, 1 week * T2 post assessment after 36 therapy sessions, expected average of 12 weeks * T3 catamnestic measurement 6 months after T2 * T4 catamnestic measurement 12 months after T2
Conners Psychopathology Scores
Time Frame: Pre-Post-Change-Design; change from baseline to psychopathology scores after 12 weeks, 6 and 12 months
Conners parents \& teacher rating scales: * T1 baseline diagnostic before therapy, 1 week * T2 post assessment after 36 therapy sessions, expected average of 12 weeks * T3 catamnestic measurement 6 months after T2 * T4 catamnestic measurement 12 months after T2
Secondary Outcomes
- Social Support(Pre-Post-Change-Design; change from baseline to social support scores after 12 weeks, 6 and 12 months)
- Self-Concept(Pre-Post-Change-Design; change from baseline to self-concept scores after 12 weeks, 6 and 12 months)
- Perceived Criticism(Pre-Post-Change-Design; change from baseline to perceived criticism scores after 12 weeks, 6 and 12 months)
- Parental Stress (ESF)(Pre-Post-Change-Design; change from baseline to parental stress scores after 12 weeks, 6 and 12 months)
- Blood/saliva samples for possible genetic correlates of therapy response(End of therapy after 36 sessions)
- Cortisol(Pre-Post-Change-Design; change from baseline to cortisol levels after 12 weeks, 6 and 12 month)